AEON Biopharma (NASDAQ:AEON) Trading 1.8% Higher – Here’s Why

AEON Biopharma, Inc. (NASDAQ:AEON) traded up 1.8% during trading on Tuesday . The company traded as high as $1.19 and last traded at $1.16. 31,233 shares were traded during mid-day trading, a decline of 80% from the average session volume of 159,659 shares. The stock had previously closed at $1.14.

Analysts Set New Price Targets

Separately, Zacks Research raised shares of AEON Biopharma to a “hold” rating in a research report on Tuesday, November 18th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, AEON Biopharma currently has an average rating of “Buy”.

AEON Biopharma Trading Up 1.8%

The stock has a fifty day simple moving average of $1.12 and a two-hundred day simple moving average of $0.98. The company has a market cap of $13.73 million, a PE ratio of 6.44 and a beta of 0.72.

Institutional Inflows and Outflows

An institutional investor recently raised its position in AEON Biopharma stock. XTX Topco Ltd raised its holdings in AEON Biopharma, Inc. (NASDAQ:AEON) by 251.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 56,852 shares of the company’s stock after acquiring an additional 40,690 shares during the quarter. XTX Topco Ltd owned 0.48% of AEON Biopharma worth $63,000 as of its most recent filing with the SEC. 22.78% of the stock is owned by institutional investors and hedge funds.

AEON Biopharma Company Profile

AEON Biopharma, Inc, formerly Allied Energy Corp., is a clinical‐stage biopharmaceutical company focused on developing and commercializing treatments for rare and orphan diseases. The company applies enzyme replacement and gene therapy platforms to address unmet medical needs in central nervous system and metabolic disorders. Its lead program, AES-103, is being developed as an enzyme replacement therapy for Crigler-Najjar syndrome, a hereditary condition characterized by high levels of unconjugated bilirubin.

Beyond AES-103, AEON Biopharma is advancing AES-201 for X-linked adrenoleukodystrophy (X-ALD), a progressive neurological disorder, and AES-104 for post–COVID-19 conditions, commonly referred to as “long COVID.” These programs are in preclinical or early clinical stages, with ongoing efforts to optimize delivery, evaluate safety profiles and establish proof of concept.